<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986684</url>
  </required_header>
  <id_info>
    <org_study_id>Hippocratio_2017</org_study_id>
    <nct_id>NCT03986684</nct_id>
  </id_info>
  <brief_title>Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease</brief_title>
  <acronym>NAFLD</acronym>
  <official_title>Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hippocration General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hippocration General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-invasive diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD) remain unmet
      medical needs. Aim of this study is to investigate the blood levels of three hormonal systems
      related to obesity, insulin resistance and inflammation in patients with different stages of
      NAFLD, in order to identify potential diagnostic markers.

      Study aim: To compare the blood levels of: a) proglucagon-derived hormones (glucagon-like
      peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment
      [MPGF]), b) follistatins-activins (follistatin-like (FSTL)3, activin B), c) IGF axis
      (insulin-like growth factor (IGF)-1, total and intact IGF binding protein (IGFBP)-3 and
      IGFBP-4, in 18 individuals with early stage NAFLD vs. 14 controls
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2017</start_date>
  <completion_date type="Actual">May 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proglucagon-derived hormones</measure>
    <time_frame>baseline</time_frame>
    <description>glucagon-like peptide GLP-1 (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proglucagon-derived hormones</measure>
    <time_frame>baseline</time_frame>
    <description>glucagon-like peptide GLP-2 (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proglucagon-derived hormones</measure>
    <time_frame>baseline</time_frame>
    <description>glicentin (pmol/l)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proglucagon-derived hormones</measure>
    <time_frame>baseline</time_frame>
    <description>oxyntomodulin (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proglucagon-derived hormones</measure>
    <time_frame>baseline</time_frame>
    <description>glucagon (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proglucagon-derived hormones</measure>
    <time_frame>baseline</time_frame>
    <description>major proglucagon fragment [MPGF]) (ng/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follistatins-activins</measure>
    <time_frame>baseline</time_frame>
    <description>follistatin-like (FSTL)3 (ng/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follistatins-activins</measure>
    <time_frame>baseline</time_frame>
    <description>activin B (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGF axis</measure>
    <time_frame>baseline</time_frame>
    <description>insulin-like growth factor (IGF)-1 (ng/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGF axis</measure>
    <time_frame>baseline</time_frame>
    <description>total and intact IGF binding protein (IGFBP)-3 and IGFBP-4 (ng/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver ultrasound</measure>
    <time_frame>baseline</time_frame>
    <description>Estimation of echogenicity, hepatomegaly, and intra-hepatic vascular blurring (1: Intermediate, 1-2: Intermediate to Moderate, 2: Moderate, 3: Severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>baseline</time_frame>
    <description>BMI is calculated as weight in kilograms divided by height in meters squared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>baseline</time_frame>
    <description>Glucose (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>baseline</time_frame>
    <description>serum aspartate transaminase (AST) (U/L), ALT (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>baseline</time_frame>
    <description>gamma-glutamyltransferase (GGT) (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>baseline</time_frame>
    <description>total cholesterol (mg/dl), triglycerides (mg/dl) and high density lipoprotein-cholesterol (HDL-C) (mg/dl), low density lipoprotein-cholesterol (LDL-C) (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>baseline</time_frame>
    <description>insulin (Î¼U/ml)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Nonalcoholic Fatty Liver</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Non-NAFLD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects from the Second Propaedeutic Department of Internal Medicine, Ippokration
        Hospital, Aristotle University of Thessaloniki, Greece
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with liver ultrasound imaging

          -  Adults

        Exclusion Criteria:

          -  The presence of any secondary cause of fatty liver, such as viral, alcoholic,
             autoimmune and drug-induced hepatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hippokration General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hippocration General Hospital</investigator_affiliation>
    <investigator_full_name>Chrysoula Boutari</investigator_full_name>
    <investigator_title>Clinical Fellow, Second Propedeutic Department of Internal Medicine, MD, MSc, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

